Mal-PEG2-NHS ester is a non-cleavable ADC linker containing the Maleimide group, 2-unit PEG, and NHS ester.
Structure of 1433997-01-3
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
100 mg | $629 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Mal-PEG2-NHS ester is a heterobifunctional ADC linker widely employed in antibody-drug conjugate design. Featuring a maleimide group and an NHS ester, this linker enables selective conjugation between thiol-containing ADC cytotoxins and lysine residues on antibodies. The PEG2 spacer introduces hydrophilicity and flexibility, which facilitates optimal linker performance in ADC linker design by reducing steric hindrance and improving solubility, thereby enhancing the stability and pharmacokinetic profile of the resulting ADC.
In ADC payload applications, the maleimide functionality allows precise thiol-reactive conjugation, while the NHS ester reacts efficiently with primary amines on antibodies. This dual reactivity supports site-specific attachment and consistent drug-to-antibody ratios (DAR), critical parameters in developing ADCs with reproducible therapeutic efficacy. The PEG2 spacer also provides controlled distance between the antibody and cytotoxic payload, maintaining antibody-antigen binding capability and minimizing aggregation.
The chemical stability of Mal-PEG2-NHS ester under physiological conditions ensures that ADC payloads remain linked during circulation, allowing controlled delivery to target tumor cells. It is compatible with a variety of ADC cytotoxins, including microtubule inhibitors, DNA-damaging agents, and other potent payloads, supporting diverse oncology-focused bioconjugation strategies.
Mal-PEG2-NHS ester is commonly used in advanced ADC linker design, providing reliable conjugation chemistry, structural flexibility, and hydrophilicity. Its combination of precise reactivity and linker stability makes it a standard tool in constructing antibody-drug conjugates with consistent performance, enhanced solubility, and optimized therapeutic potential for targeted cancer therapy.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00442 | Mal-PEG6-NHS | 1137109-21-7 | |
BADC-00448 | Mal-PEG-NHS | 1260092-50-9 | |
BADC-00443 | Mal-PEG5-NHS | 1315355-92-0 | |
BADC-00450 | Mal-PEG4-NHS | 1325208-25-0 | |
BADC-01679 | Mal-PEG2-Val-Cit-PABA-PNP | 1345681-52-8 | |
BADC-00936 | Mal-PEG2-acid | 1374666-32-6 | |
BADC-00449 | Mal-PEG4-PFP | 1415800-42-8 | |
BADC-00603 | Mal-PEG3-NHS ester | 1537892-36-6 | |
BADC-00966 | Mal-PEG4-VC-PAB-DMEA | 1569261-93-3 | |
BADC-00499 | Mal-PEG6-NHS ester | 1599472-25-9 |
What is Mal-PEG2-NHS ester?
Mal-PEG2-NHS ester is a PEGylated heterobifunctional linker used in ADCs and protein conjugation. The maleimide group reacts with thiols, while the NHS ester reacts with amines, and the PEG2 spacer enhances solubility and reduces steric hindrance during conjugation.
15/8/2021
Could you please advise how Mal-PEG2-NHS ester should be stored?
It should be stored in a dry, cool, and dark environment, preferably under inert gas. Proper storage preserves the reactivity of maleimide and NHS groups, ensuring stable conjugation and reproducible experimental results.
9/7/2022
Could you kindly advise the specifications of Mal-PEG2-NHS ester?
Specifications include PEG2 length, molecular weight, reactive group ratios, and solubility. These details support experimental planning and conjugation strategy without providing specific purity data.
2/9/2020
Good afternoon! Could you kindly let me know if there are support documents for Mal-PEG2-NHS ester?
Yes, structural diagrams, handling instructions, and recommended conjugation protocols are provided. These documents assist researchers in achieving reproducible results in ADC and bioconjugation studies.
5/6/2018
Dear BOC Sciences, how is Mal-PEG2-NHS ester quality typically assessed?
Quality is assessed using NMR, LC-MS, and HPLC to confirm chemical structure, functional group integrity, and stability. These analyses ensure reliability for ADC linker applications and conjugation experiments.
25/8/2019
— Dr. Kevin Hughes, Biochemist (UK)
Mal-PEG2-NHS ester enabled highly efficient antibody modification, and the product purity was excellent.
2/9/2020
— Ms. Julia Fischer, Research Scientist (Germany)
BOC Sciences supplied Mal-PEG2-NHS ester with consistent performance, crucial for our ADC linker optimization.
25/8/2019
— Dr. Robert Clark, ADC Development Scientist (USA)
Excellent solubility and stability of Mal-PEG2-NHS ester facilitated our protein conjugation studies without unexpected aggregation.
5/6/2018
— Dr. Sophie Laurent, Medicinal Chemist (France)
Using Mal-PEG2-NHS ester, we achieved reproducible PEGylation with minimal side reactions.
15/8/2021
— Mr. Daniel Evans, Senior Scientist (Canada)
The product documentation and batch QC for Mal-PEG2-NHS ester were comprehensive, easing regulatory submissions.
— Dr. Maria Thompson, Bioconjugation Specialist (USA)
Technical guidance from BOC Sciences helped optimize Mal-PEG2-NHS ester conjugation, improving our ADC yield.
9/7/2022
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.